Will there ever be a universal Staphylococcus aureus vaccine?

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 9, 2013, Pages 1865-1876

  Pier, Gerald B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antibody; Clinical trials; Immunotherapy; S. aureus; T cells; Vaccines

Indexed keywords

BACTERIAL POLYSACCHARIDE; N ACETYLGLUCOSAMINE; POLY N ACETYL GLUCOSAMINE; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; DISEASE ASSOCIATION; DISEASE MODEL; DRUG DESIGN; HUMAN; IMMUNE RESPONSE; INFECTION RESISTANCE; NONHUMAN; PATIENT SELECTION; RECURRENCE RISK; RECURRENT INFECTION; REVIEW; STAPHYLOCOCCUS INFECTION; TH17 CELL; VACCINE PRODUCTION;

ANTIBODY; CLINICAL TRIALS; IMMUNOTHERAPY; S. AUREUS; T-CELLS; VACCINES;

COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84884615646     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25182     Document Type: Review

References (132)

1. Nanra JS, Timofeyeva Y, Buitrago SM, Sellman BR, Dilts DA, Fink P, et al. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine 2009; 27:3276-80; PMID:19200819; http://dx.doi.org/10.1016/j.vaccine. 2009.01.062
2. Golubchik T, Batty EM, Miller RR, Farr H, Young BC, Larner-Svensson H, et al. Within-host evolution of Staphylococcus aureus during asymptomatic carriage. PLoS One 2013; 8:e61319; PMID:23658690; http://dx.doi.org/10.1371/ journal.pone.0061319
3. Nethercott C, Mabbett AN, Totsika M, Peters P, Ortiz JC, Nimmo GR, et al. Molecular Characterization of Endocarditis-Associated Staphylococcus aureus. J Clin Microbiol 2013; 51:2131-8; PMID:23616460; http://dx.doi.org/10.1128/JCM. 00651-13
4. Peacock SJ, Moore CE, Justice A, Kantzanou M, Story L, Mackie K, et al. Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infect Immun 2002; 70:4987-96; PMID:12183545; http://dx.doi.org/10.1128/IAI.70.9.4987-4996.2002
5. Bonventre PF, Linnemann C, Weckbach LS, Staneck JL, Buncher CR, Vigdorth E, et al. Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. J Infect Dis 1984; 150:662-6; PMID:6491377; http://dx.doi.org/10.1093/infdis/150.5.662
6. Christensson B, Hedström SA. Serological response to toxic shock syndrome toxin in Staphylococcus aureus infected patients and healthy controls. Acta Pathol Microbiol Immunol Scand B 1985; 93:87-90; PMID:4013745
7. Johnson HM, Russell JK, Pontzer CH. Staphylococcal enterotoxin microbial superantigens. FASEB J 1991; 5:2706-12; PMID:1916093
8. Novick RP. Mobile genetic elements and bacterial toxinoses: the superantigen-encoding pathogenicity islands of Staphylococcus aureus. Plasmid 2003; 49:93-105; PMID:12726763; http://dx.doi.org/10.1016/S0147-619X(02)00157-9
9. Dreisbach A, Hempel K, Buist G, Hecker M, Becher D, van Dijl JM. Profiling the surfacome of Staphylococcus aureus. Proteomics 2010; 10:3082-96; PMID:20662103; http://dx.doi.org/10.1002/pmic.201000062
10. Dreisbach A, van der Kooi-Pol MM, Otto A, Gronau K, Bonarius HP, Westra H, et al. Surface shaving as a versatile tool to profile global interactions between human serum proteins and the Staphylococcus aureus cell surface. Proteomics 2011; 11:2921-30; PMID:21674804; http://dx.doi.org/10.1002/pmic. 201100134
11. Klevens RM, Edwards JR, Gaynes RP; National Nosocomial Infections Surveillance System. The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin Infect Dis 2008; 47:927-30; PMID:18752440; http://dx.doi.org/10.1086/591698
12. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al.; Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-71; PMID:17940231; http://dx.doi.org/10.1001/jama.298.15. 1763
13. Forstner C, Dungl C, Tobudic S, Mitteregger D, Lagler H, Burgmann H. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence. Clin Microbiol Infect 2013; 19:E291-7; PMID:23490021; http://dx.doi.org/10.1111/1469-0691.12169
14. Peyrani P, Allen M, Wiemken TL, Haque NZ, Zervos MJ, Ford KD, et al.; IMPACT-HAP Study Group. Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton-Valentine leukocidin gene. Clin Infect Dis 2011; 53:766-71; PMID:21880581; http://dx.doi.org/10. 1093/cid/cir541
15. de Kraker MEA, Davey PG, Grundmann H; BURDEN study group. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med 2011; 8:e1001104; PMID:22022233; http://dx.doi.org/10.1371/journal.pmed. 1001104
16. Lambert ML, Suetens C, Savey A, Palomar M, Hiesmayr M, Morales I, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 2011; 11:30-8; PMID:21126917; http://dx.doi.org/10. 1016/S1473-3099(10)70258-9
17. Mediavilla JR, Chen L, Mathema B, Kreiswirth BN. Global epidemiology of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA). Curr Opin Microbiol 2012; 15:588-95; PMID:23044073; http://dx.doi.org/10.1016/j.mib. 2012.08.003
18. Malachowa N, Kobayashi SD, DeLeo FR. Community-associated methicillin-resistant Staphylococcus aureus and athletes. Phys Sportsmed 2012; 40:13-21; PMID:22759601; http://dx.doi.org/10.3810/psm.2012.05.1960
19. Otto M. MRSA virulence and spread. Cell Microbiol 2012; 14:1513-21; PMID:22747834; http://dx.doi.org/10.1111/j.1462-5822.2012.01832.x
20. Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, McNeely T, et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006; 74:2215-23; PMID:16552052; http://dx.doi.org/10.1128/IAI.74.4.2215-2223.2006
21. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 2001; 184:1572-80; PMID:11740733; http://dx.doi.org/10.1086/324430
22. Welch PG, Fattom A, Moore J Jr., Schneerson R, Shiloach J, Bryla DA, et al. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J Am Soc Nephrol 1996; 7:247-53; PMID:8785394
23. Fattom AI, Sarwar J, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 1996; 64:1659-65; PMID:8613375
24. Weisman LE, Fischer GW, Thackray HM, Johnson KE, Schuman RF, Mandy GT, et al. Safety and pharmacokinetics of a chimerized antilipoteichoic acid monoclonal antibody in healthy adults. Int Immunopharmacol 2009; 9:639-44; PMID:19268719; http://dx.doi.org/10.1016/j.intimp.2009.02.008
25. Burnie JP, Matthews RC, Carter T, Beaulieu E, Donohoe M, Chapman C, et al. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect Immun 2000; 68:3200-9; PMID:10816464; http://dx.doi.org/10.1128/IAI.68.6.3200-3209.2000
26. Proctor RA. Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis 2012; 54:1179-86; PMID:22354924; http://dx.doi.org/10.1093/cid/ cis033
27. Jansen KU, Girgenti DQ, Scully IL, Anderson AS. Vaccine review: "Staphyloccocus aureus vaccines: Problems and prospects". Vaccine 2013; 31:2723-30; PMID:23624095; http://dx.doi.org/10.1016/j.vaccine.2013.04.002
28. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 2013; 309:1368-78; PMID:23549582; http://dx.doi.org/10.1001/jama.2013.3010
29. Spellberg B, Daum R. Development of a vaccine against Staphylococcus aureus. Semin Immunopathol 2012; 34:335-48; PMID:22080194; http://dx.doi.org/10. 1007/s00281-011-0293-5
30. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 2012; 54:560-7; PMID:22186773; http://dx.doi.org/10.1093/cid/ cir828
31. Thomsen I, Dudney H, Creech CB. Searching for the holy grail of a staphylococcal vaccine. Hum Vaccin 2010; 6:1068-70; PMID:21150276; http://dx.doi.org/10.4161/hv.6.12.12917
32. Avery TR, Kleinman KP, Klompas M, Aschengrau A, Huang SS. Inclusion of 30-day postdischarge detection triples the incidence of hospital-onset methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2012; 33:114-21; PMID:22227979; http://dx.doi.org/10.1086/663714
33. Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003; 36:281-5; PMID:12539068; http://dx.doi.org/10.1086/345955
34. Duffy J, Dumyati G, Bulens S, Namburi S, Gellert A, Fridkin SK, et al. Community-onset invasive methicillin-resistant Staphylococcus aureus infections following hospital discharge. Am J Infect Control 2013; In press; PMID:23394888; http://dx.doi.org/10.1016/j.ajic.2012.10.020.
35. Skurnik D, Kropec A, Roux D, Theilacker C, Huebner J, Pier GB. Natural antibodies in normal human sera inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy. Clin Infect Dis 2012; 205:1709-18
36. Skurnik D, Merighi M, Grout M, Gadjeva M, Maira-Litran T, Ericsson M, et al. Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. J Clin Invest 2010; 120:3220-33; PMID:20739753; http://dx.doi.org/10.1172/JCI42748
37. Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O. Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med 2010; 207:1863-70; PMID:20713595; http://dx.doi.org/10.1084/jem. 20092514
38. Kim HK, Thammavongsa V, Schneewind O, Missiakas D. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol 2012; 15:92-9; PMID:22088393; http://dx.doi.org/10.1016/j.mib.2011.10.012
39. Proctor RA. Is there a future for a Staphylococcus aureus vaccine? Vaccine 2012; 30:2921-7; PMID:22115633; http://dx.doi.org/10.1016/j.vaccine. 2011.11.006
40. Miller LS, Cho JS. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol 2011; 11:505-18; PMID:21720387; http://dx.doi.org/ 10.1038/nri3010
41. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009; 30:108-19; PMID:19144317; http://dx.doi.org/10.1016/j.immuni.2008.11.009
42. Ardura MI, Banchereau R, Mejias A, Di Pucchio T, Glaser C, Allantaz F, et al. Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections. PLoS One 2009; 4:e5446; PMID:19424507; http://dx.doi.org/10.1371/journal.pone.0005446
43. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008; 226:57-79; PMID:19161416; http://dx.doi.org/10.1111/j.1600-065X.2008. 00699.x
44. Roos D, Kuhns DB, Maddalena A, Roesler J, Lopez JA, Ariga T, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis 2010; 45:246-65; PMID:20729109; http://dx.doi.org/10.1016/j.bcmd.2010.07.012
45. Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006; 85:193-202; PMID:16862044; http://dx.doi.org/10.1097/01.md.0000229482.27398.ad
46. Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol 2010; 38:3-10; PMID:19504359; http://dx.doi.org/10.1007/s12016-009-8136-z
47. Kurebayashi Y, Nagai S, Ikejiri A, Koyasu S. Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes Cells 2013; 18:247-65; PMID:23383714; http://dx.doi.org/10.1111/ gtc.12039
48. Kolata J, Bode LG, Holtfreter S, Steil L, Kusch H, Holtfreter B, et al. Distinctive patterns in the human antibody response to Staphylococcus aureus bacteremia in carriers and non-carriers. Proteomics 2011; 11:3914-27; PMID:21805632; http://dx.doi.org/10.1002/pmic.201000760
49. den Reijer PM, Lemmens-den Toom N, Kant S, Snijders SV, Boelens H, Tavakol M, et al. Characterization of the humoral immune response during Staphylococcus aureus bacteremia and global gene expression by Staphylococcus aureus in human blood. PLoS One 2013; 8:e53391; PMID:23308212; http://dx.doi.org/10.1371/journal.pone.0053391
50. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5:e1000703; PMID:20041174; http://dx.doi.org/10.1371/journal.ppat.1000703
51. Narita K, Hu DL, Mori F, Wakabayashi K, Iwakura Y, Nakane A. Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A. Infect Immun 2010; 78:4234-42; PMID:20679443; http://dx.doi.org/10. 1128/IAI.00447-10
52. Yoong P, Pier GB. Immune-activating properties of Panton-Valentine leukocidin improve the outcome in a model of methicillin-resistant Staphylococcus aureus pneumonia. Infect Immun 2012; 80:2894-904; PMID:22665379; http://dx.doi.org/10.1128/IAI.06360-11
53. Hermos CR, Yoong P, Pier GB. High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureusassociated skin and soft-tissue infection. Clin Infect Dis 2010; 51:1138-46; PMID:20946065; http://dx.doi.org/10.1086/656742
54. Verkaik NJ, Dauwalder O, Antri K, Boubekri I, de Vogel CP, Badiou C, et al. Immunogenicity of toxins during Staphylococcus aureus infection. Clin Infect Dis 2010; 50:61-8; PMID:19947854; http://dx.doi.org/10.1086/648673
55. Jacobsson G, Colque-Navarro P, Gustafsson E, Andersson R, Möllby R. Antibody responses in patients with invasive Staphylococcus aureus infections. Eur J Clin Microbiol Infect Dis 2010; 29:715-25; PMID:20383551; http://dx.doi.org/10.1007/s10096-010-0919-x
56. Holtfreter S, Jursa-Kulesza J, Masiuk H, Verkaik NJ, de Vogel C, Kolata J, et al. Antibody responses in furunculosis patients vaccinated with autologous formalin-killed Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 2011; 30:707-17; PMID:21509478; http://dx.doi.org/10.1007/s10096-010-1136-3
57. Adhikari RP, Ajao AO, Aman MJ, Karauzum H, Sarwar J, Lydecker AD, et al. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis 2012; 206:915-23; PMID:22807524; http://dx.doi.org/10.1093/infdis/jis462
58. Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, et al. A serologic correlate of protective immunity against communityonset Staphylococcus aureus infection. Clin Infect Dis 2013; 56:1554-61; PMID:23446627; http://dx.doi.org/10.1093/cid/cit123
59. Huang SS, Hinrichsen VL, Datta R, Spurchise L, Miroshnik I, Nelson K, et al. Methicillin-resistant Staphylococcus aureus infection and hospitalization in high-risk patients in the year following detection. PLoS One 2011; 6:e24340; PMID:21949707; http://dx.doi.org/10.1371/journal.pone.0024340
60. Huang SS, Diekema DJ, Warren DK, Zuccotti G, Winokur PL, Tendolkar S, et al. Strain-relatedness of methicillin-resistant Staphylococcus aureus isolates recovered from patients with repeated infection. Clin Infect Dis 2008; 46:1241-7; PMID:18444862; http://dx.doi.org/10.1086/529381
61. Kobayashi SD, Malachowa N, Whitney AR, Braughton KR, Gardner DJ, Long D, et al. Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. J Infect Dis 2011; 204:937-41; PMID:21849291; http://dx.doi.org/10.1093/infdis/jir441
62. Otto M. Basis of virulence in communityassociated methicillin-resistant Staphylococcus aureus. Annu Rev Microbiol 2010; 64:143-62; PMID:20825344; http://dx.doi.org/10.1146/annurev.micro.112408.134309
63. Li M, Cheung GY, Hu J, Wang D, Joo HS, Deleo FR, et al. Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains. J Infect Dis 2010; 202:1866-76; PMID:21050125; http://dx.doi.org/10.1086/657419
64. Gauduchon V, Cozon G, Vandenesch F, Genestier AL, Eyssade N, Peyrol S, et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004; 189:346-53; PMID:14722901; http://dx.doi.org/10.1086/380909
65. Srinivasan A, Seifried S, Zhu L, Srivastava DK, Flynn PM, Shenep JL, et al. Panton-Valentine leukocidinpositive methicillin-resistant Staphylococcus aureus infections in children with cancer. Pediatr Blood Cancer 2009; 53:1216-20; PMID:19731325; http://dx.doi.org/10.1002/pbc.22254
66. Orscheln RC, Hunstad DA, Fritz SA, Loughman JA, Mitchell K, Storch EK, et al. contribution of genetically restricted, methicillin-susceptible strains to the ongoing epidemic of community-acquired Staphylococcus aureus infections. Clin Infect Dis 2009; 49:536-42; PMID:19589082; http://dx.doi.org/10.1086/600881
67. Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF, Barriere SL, et al. Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J Clin Microbiol 2009; 47:3952-7; PMID:19846653; http://dx.doi.org/10.1128/JCM.01643-09
68. Yoong P, Pier GB. Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci U S A 2010; 107:2241-6; PMID:20133867; http://dx.doi.org/10.1073/pnas.0910344107
69. Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008; 198:1166-70; PMID:18729780; http://dx.doi.org/10.1086/592053
70. Foletti D, Strop P, Shaughnessy L, Hasa-Moreno A, Casas MG, Russell M, et al. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus α-hemolysin. J Mol Biol 2013; 425:1641-54; PMID:23416200; http://dx.doi.org/10.1016/j.jmb.2013.02.008
71. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969; 129:1367-84; PMID:4977283; http://dx.doi.org/10.1084/jem.129.6.1367
72. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969; 129:1327-48; PMID:4977281; http://dx.doi.org/10.1084/jem.129.6.1327
73. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307-26; PMID:4977280; http://dx.doi.org/10.1084/jem.129.6.1307
74. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med 1969; 129:1385-95; PMID:4977284; http://dx.doi.org/10.1084/jem.129.6.1385
75. Gold R, Artenstein MS. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ 1971; 45:279-82; PMID:5316907
76. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine.N Engl J Med 1970; 282:417-20; PMID:4983754; http://dx.doi.org/10.1056/ NEJM197002192820803
77. Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother 2009; 53:2879-86; PMID:19380597; http://dx.doi.org/10.1128/AAC.01565-08
78. Shinefield HR. Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible? Vaccine 2006; 24(Suppl 2):S2-65, 9; PMID:16823932; http://dx.doi.org/10.1016/j.vaccine.2005.01.126
79. Vernachio J, Bayer AS, Le T, Chai YL, Prater B, Schneider A, et al. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother 2003; 47:3400-6; PMID:14576094; http://dx.doi.org/10.1128/A AC.47.11.3400-3406.2003
80. Joshi A, Pancari G, Cope L, Bowman EP, Cua D, Proctor RA, et al. Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum Vaccin Immunother 2012; 8:336-46; PMID:22327491; http://dx.doi.org/10.4161/hv. 18946
81. Kim HK, DeDent A, Cheng AG, McAdow M, Bagnoli F, Missiakas DM, et al. IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 2010; 28:6382-92; PMID:20226248; http://dx.doi.org/10.1016/j.vaccine.2010.02.097
82. Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syribeys PJ, Gorovits EL, et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun 2003; 71:6864-70; PMID:14638774; http://dx.doi.org/10.1128/IAI.71.12.6864-6870.2003
83. Brady RA, Mocca CP, Prabhakara R, Plaut RD, Shirtliff ME, Merkel TJ, et al. Evaluation of genetically inactivated alpha toxin for protection in multiple mouse models of Staphylococcus aureus infection. PLoS One 2013; 8:e63040; PMID:23658662; http://dx.doi.org/10.1371/journal.pone.0063040
84. Gening ML, Maira-Litrán T, Kropec A, Skurnik D, Grout M, Tsvetkov YE, et al. Synthetic β-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens. Infect Immun 2010; 78:764-72; PMID:19948836; http://dx.doi.org/10.1128/IAI. 01093-09
85. Maira-Litrán T, Kropec A, Goldmann DA, Pier GB. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-β-(1-6)- glucosamine. Infect Immun 2005; 73:6752-62; PMID:16177353; http://dx.doi.org/10. 1128/IAI.73.10.6752-6762.2005
86. Toltzis P, Jacobs MR. The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use. Infect Dis Clin North Am 2005; 19:629-45; PMID:16102653; http://dx.doi.org/10.1016/j.idc.2005.05.008
87. Ladhani SN. Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom. Clin Ther 2012; 34:385-99; PMID:22244051; http://dx.doi.org/10.1016/j.clinthera.2011.11.027
88. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511-20; PMID:20410516; http://dx.doi.org/10.1056/NEJMra0906357
89. Engels EA, Lau J. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2000; CD001261; PMID:10796623
90. Cocchiaro JL, Gomez MI, Risley A, Solinga R, Sordelli DO, Lee JC. Molecular characterization of the capsule locus from non-typeable Staphylococcus aureus. Mol Microbiol 2006; 59:948-60; PMID:16420363; http://dx.doi.org/10. 1111/j.1365-2958.2005.04978.x
91. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004; 17:218-34; PMID:14726462; http://dx.doi.org/10.1128/CMR.17. 1.218-234.2004
92. McKenney D, Pouliot KL, Wang Y, Murthy V, Ulrich M, Döring G, et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 1999; 284:1523-7; PMID:10348739; http://dx.doi.org/10.1126/science.284.5419.1523
93. Maira-Litrán T, Kropec A, Abeygunawardana C, Joyce J, Mark G 3rd, Goldmann DA, et al. Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide. Infect Immun 2002; 70:4433-40; PMID:12117954; http://dx.doi.org/10.1128/IAI.70.8.4433-4440.2002
94. Sutter DE, Summers AM, Keys CE, Taylor KL, Frasch CE, Braun LE, et al. Capsular serotype of Staphylococcus aureus in the era of communityacquired MRSA. FEMS Immunol Med Microbiol 2011; 63:16-24; PMID:21631600; http://dx.doi.org/10. 1111/j.1574-695X.2011.00822.x
95. Melles DC, Taylor KL, Fattom AI, van Belkum A. Serotyping of Dutch Staphylococcus aureus strains from carriage and infection. FEMS Immunol Med Microbiol 2008; 52:287-92; PMID:18218024; http://dx.doi.org/10.1111/j.1574-695X. 2008.00376.x
96. von Eiff C, Taylor KL, Mellmann A, Fattom AI, Friedrich AW, Peters G, et al. Distribution of capsular and surface polysaccharide serotypes of Staphylococcus aureus. Diagn Microbiol Infect Dis 2007; 58:297-302; PMID:17376630; http://dx.doi.org/10.1016/j.diagmicrobio.2007.01.016
97. Verdier I, Durand G, Bes M, Taylor KL, Lina G, Vandenesch F, et al. Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests. J Clin Microbiol 2007; 45:725-9; PMID:17202275; http://dx.doi.org/10.1128/JCM.01572-06
98. Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 1993; 61:1023-32; PMID:8432585
99. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-6; PMID:11844850; http://dx.doi.org/10. 1056/NEJMoa011297
100. Fattom A, Fuller S, Propst M, Winston S, Muenz L, He D, et al. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine 2004; 23:656-63; PMID:15542186; http://dx.doi.org/10.1016/j.vaccine. 2004.06.043
101. Hudson LO, Murphy CR, Spratt BG, Enright MC, Elkins K, Nguyen C, et al. Diversity of methicillinresistant Staphylococcus aureus(MRSA) strains isolated from inpatients of 30 hospitals in Orange County, California. PLoS One 2013; 8:e62117; PMID:23637976; http://dx.doi.org/10.1371/journal.pone.0062117
102. Montgomery CP, Boyle-Vavra S, Adem PV, Lee JC, Husain AN, Clasen J, et al. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis 2008; 198:561-70; PMID:18598194; http://dx.doi.org/10.1086/590157
103. Shopsin B, Eaton C, Wasserman GA, Mathema B, Adhikari RP, Agolory S, et al. Mutations in agr do not persist in natural populations of methicillin-resistant Staphylococcus aureus. J Infect Dis 2010; 202:1593-9; PMID:20942648; http://dx.doi.org/10.1086/656915
104. Traber KE, Lee E, Benson S, Corrigan R, Cantera M, Shopsin B, et al. agr function in clinical Staphylococcus aureus isolates. Microbiology 2008; 154:2265-74; PMID:18667559; http://dx.doi.org/10.1099/mic.0.2007/011874-0
105. Shopsin B, Drlica-Wagner A, Mathema B, Adhikari RP, Kreiswirth BN, Novick RP. Prevalence of agr dysfunction among colonizing Staphylococcus aureus strains. J Infect Dis 2008; 198:1171-4; PMID:18752431; http://dx.doi.org/10. 1086/592051
106. Smyth DS, Kafer JM, Wasserman GA, Velickovic L, Mathema B, Holzman RS, et al. Nasal carriage as a source of agr-defective Staphylococcus aureus bacteremia. J Infect Dis 2012; 206:1168-77; PMID:22859823; http://dx.doi.org/10. 1093/infdis/jis483
107. Luong T, Sau S, Gomez M, Lee JC, Lee CY. Regulation of Staphylococcus aureus capsular polysaccharide expression by agr and sarA. Infect Immun 2002; 70:444-50; PMID:11796569; http://dx.doi.org/10.1128/IAI.70.2.444-450.2002
108. Pozzi C, Wilk K, Lee JC, Gening M, Nifantiev N, Pier GB. Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens. PLoS One 2012; 7:e46648; PMID:23077517; http://dx.doi.org/10.1371/journal.pone.0046648
109. Maira-Litrán T, Bentancor LV, Bozkurt-Guzel C, O'Malley JM, Cywes-Bentley C, Pier GB. Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A. PLoS One 2012; 7:e43813; PMID:22970144; http://dx.doi.org/10.1371/journal. pone.0043813
110. Kelly-Quintos C, Cavacini LA, Posner MR, Goldmann D, Pier GB. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-Nacetylglucosamine. Infect Immun 2006; 74:2742-50; PMID:16622211; http://dx.doi.org/10.1128/IAI.74.5.2742-2750.2006
111. Kropec A, Maira-Litran T, Jefferson KK, Grout M, Cramton SE, Götz F, et al. Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection. Infect Immun 2005; 73:6868-76; PMID:16177366; http://dx.doi.org/10.1128/IAI.73.10.6868-6876. 2005
112. Joyce JG, Abeygunawardana C, Xu Q, Cook JC, Hepler R, Przysiecki CT, et al. Isolation, structural characterization, and immunological evaluation of a high-molecular-weight exopolysaccharide from Staphylococcus aureus. Carbohydr Res 2003; 338:903-22; PMID:12681914; http://dx.doi.org/10.1016/S0008-6215(03) 00045-4
113. Cerca N, Jefferson KK, Maira-Litrán T, Pier DB, Kelly-Quintos C, Goldmann DA, et al. Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-β-(1-6)-glucosamine. Infect Immun 2007; 75:3406-13; PMID:17470540; http://dx.doi.org/10.1128/IAI.00078-07
114. Vlock D, Lee JC, Kropec-Huebner A, Pier GB. Pre-clinical and initial phase I evaluations of a fully human monoclonal antibody directed against the PNAG surface polysaccharide on Staphylococcus aureus. Abstracts of the 50th ICAAC 2010; Abstract G1-1654/329 2010.
115. Wang X, Preston JF 3rd, Romeo T. The pgaABCD locus of Escherichia coli promotes the synthesis of a polysaccharide adhesin required for biofilm formation. J Bacteriol 2004; 186:2724-34; PMID:15090514; http://dx.doi.org/10. 1128/JB.186.9.2724-2734.2004
116. Parise G, Mishra M, Itoh Y, Romeo T, Deora R. Role of a putative polysaccharide locus in Bordetella biofilm development. J Bacteriol 2007; 189:750-60; PMID:17114249; http://dx.doi.org/10.1128/JB.00953-06
117. Cerca N, Maira-Litrán T, Jefferson KK, Grout M, Goldmann DA, Pier GB. Protection against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide. Proc Natl Acad Sci U S A 2007; 104:7528-33; PMID:17446272; http://dx.doi.org/10.1073/ pnas.0700630104
118. Izano EA, Sadovskaya I, Vinogradov E, Mulks MH, Velliyagounder K, Ragunath C, et al. Poly-Nacetylglucosamine mediates biofilm formation and antibiotic resistance in Actinobacillus pleuropneumoniae. Microb Pathog 2007; 43:1-9; PMID:17412552; http://dx.doi.org/10.1016/j.micpath.2007.02.004
119. Skurnik D, Davis MR Jr., Benedetti D, Moravec KL, Cywes-Bentley C, Roux D, et al. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis 2012; 205:1709-18; PMID:22448004; http://dx.doi.org/10.1093/infdis/jis254
120. Cywes-Bentley C, Skurnik D, Zaidi T, Roux D, Deoliveira RB, Garrett WS, et al. Antibody to a conserved antigenic target is protective against diverse
121. Fitzgerald SF, O'Gorman J, Morris-Downes MM, Crowley RK, Donlon S, Bajwa R, et al. A 12-year review of Staphylococcus aureus bloodstream infections in haemodialysis patients: more work to be done. J Hosp Infect 2011; 79:218-21; PMID:21856042; http://dx.doi.org/10.1016/j.jhin.2011.06.015
122. DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 2007; 151:260-5, e1; PMID:17719934; http://dx.doi.org/10.1016/j.jpeds.2007.04. 060
123. Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 2011; 128:271-9; PMID:21788224; http://dx.doi.org/10.1542/peds.2010-3081
124. Pahys JM, Pahys JR, Cho SK, Kang MM, Zebala LP, Hawasli AH, et al. Methods to decrease postoperative infections following posterior cervical spine surgery. J Bone Joint Surg Am 2013; 95:549-54; PMID:23515990; http://dx.doi.org/10.2106/JBJS.K.00756
125. Fry DE. The continued challenge of Staphylococcus aureus in the surgical patient. Am Surg 2013; 79:1-10; PMID:23317583
126. Goyal N, Miller A, Tripathi M, Parvizi J. Methicillin-resistant Staphylococcus aureus (MRSA): colonisation and pre-operative screening. Bone Joint J 2013; 95-B:4-9; PMID:23307666; http://dx.doi.org/10.1302/0301-620X.95B1. 27973
127. Marshall C, Richards M, McBryde E. Do active surveillance and contact precautions reduce MRSA acquisition? A prospective interrupted time series. PLoS One 2013; 8:e58112; PMID:23555568; http://dx.doi.org/10.1371/journal.pone. 0058112
128. Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013; 368:533-42; PMID:23388005; http://dx.doi.org/10.1056/NEJMoa1113849
129. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 2006; 103:16942-7; PMID:17075065; http://dx.doi.org/10.1073/pnas.0606863103
130. Tsuji T, Shimizu T, Sasaki K, Tsukamoto K, Arimitsu H, Ochi S, et al. A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for crossprotection against Shiga toxin types 1 and 2. Vaccine 2008; 26:2092-9; PMID:18387720; http://dx.doi.org/10.1016/j.vaccine.2008.02.034
131. Serna A 4th, Boedeker EC. Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections. Curr Opin Gastroenterol 2008; 24:38-47; PMID:18043231; http://dx.doi.org/10.1097/MOG.0b013e3282f2dfb8
132. Gerding DN. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. Discov Med 2012; 13:75-83; PMID:22284786